top of page

In absolute numbers, for women taking HRT for five years the increased risk reported in the meta- analysis was as follows:

  • For women taking continuous combined HRT for five years from the age of 50, the risk of developing breast cancer between the age of 50 and 69 goes up by 1 extra case in 50 over 20 years from a back- groundriskof3outof50womento4outof50 women.

  • For women taking sequential combined HRT for five years from the age of 50, the risk of developing breast cancer between the age of 50 and 69 goes up by 1 extra case in 70 over 20 years from a back- groundriskof4outof70womento5outof70 women.

  • For women taking estrogen only HRT for five years from the age of 50, the risk of developing breast cancer between the age of 50 and 69 goes up by 1 extra case in 200 over 20 years from a background risk of 13 out of 200 women to 14 out of 200 women.

 42-year-old female, with no history of medical conditions and has NKDA. She does not smoke, drink alcohol or take recreational drugs. Her BMI is 18 and she exercises 5 times a week, sometimes more. She started taking Citalopram 10mg OD 4 weeks ago for anxiety/health anxiety. She has experienced night sweats and dry skin since commencing this medication. She has had 3 previous LSCS in 2015, 2018 and 2021 then had a Mirena coil inserted following the birth of her last baby. She currently does not have any periods or bleeding since she has had the coil. Previously when she had gone through episodes of intense exercise routine, her periods stopped for a few years. She recently has been diagnosed with the BRCA2 gene and has been advised to have surgery to remove her fallopian tubes +/- ovaries. There is no family history of breast or ovarian cancer, her sisters and cousins are awaiting the results of the BRCA2 gene test. The only family history of note is that her Grandfather had prostate cancer and her sister had a DVT following a long-haul flight. The patient would like to discuss her options for hormone replacement therapy following the surgery she will have.
Women who are carriers of the BRCA1 and BRCA2 gene mutation who have undergone risk-reducing BSO, can receive add-back HRT and this has not been shown to diminish the risk-reducing benefit of BSO on subsequent risk of breast cancer diagnosis. A meta- analysis and recent systematic review on this showed no increase in the risk of breast cancer in women with BRCA1 and BRCA2 mutations using HRT after risk- reducing BSO.
​
​
​
​
image.png
bottom of page